AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

ITRM(Delisted)

Iterum Therapeutics·NASDAQ
--
--(--)
3.91 / 10
Neutral

Fund‑flow metrics are strong (7.82/10) with positive inflows across all size segments. Analyst coverage is thin: one strong‑buy rating, but historical performance is negative and market sentiment is neutral. Combined with a 79% price drop, outlook remains uncertain.

FundamentalSentiment(3.91)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-05-08
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%